Press releases
- Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
- Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024
- Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
- Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
- Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
- Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
- Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
- Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today
- Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024
More ▼
Key statistics
On Friday, Eupraxia Pharmaceuticals Inc (EPRX:NAQ) closed at 2.71, 9.27% above its 52-week low of 2.48, set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.72 |
---|---|
High | 2.87 |
Low | 2.71 |
Bid | 2.53 |
Offer | 2.82 |
Previous close | 2.76 |
Average volume | 55.61k |
---|---|
Shares outstanding | 35.62m |
Free float | 33.16m |
P/E (TTM) | -- |
Market cap | 130.02m CAD |
EPS (TTM) | -1.65 CAD |
Data delayed at least 15 minutes, as of May 31 2024 19:29 BST.
More ▼